Recent data from Pfizer’s mid-stage study, VESPER-3, shows promising results for the obesity drug berobenatide, which can be dosed monthly. Patients in the study lost up to 12.1% of their weight over 28 weeks, and data suggests continued weight loss with monthly dosing. However, the rate of weight loss remains lower compared to Eli Lilly’s Zepbound, which may pose competitive challenges in the market.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/06/06/pfizer-obesity-drug-berobenatide-metsera-results/
